The crux of the program is the already nationally regarded heart valve program headed by Dr Alex Incani and Dr Karl Poon. The program has treated almost 300 patients with internationally published and presented data of patient outcomes.
With further funding it is hoped more patients will be made aware of early disease detection, offering hope for treatment when they thought surgical aortic valve treatment was the only option.
Most importantly, the QHI funding will allow patients to access new transcatheter therapy through financial support from industry partners. New transcatheter devices are traditionally not funded by Medicare. These devices are generally very expensive and not affordable for most patients. With collaboration with industry partners and benefactors, it is envisaged patients who otherwise would have no hope will be treated, and their lives improved.
Anticipated programs include:
- Tavi related studies with S3 Device and peri-procedural evaluation;
- Research and trial procedures of:
- New mitral therapy;
- New tricuspid therapy;
- Renal denervation;
- Balloon pulmonary angioplasty;
- New generation Tavi;
- Leadless pacemakers, and
- Industry-funded registries and feasibility studies.